sage-10k_20161231.htm
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
On a Roll: FDA Calls Sage's Depression Drug a Breakthrough | BioSpace
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets
Breakthrough Agitation Agent; Demi Lovato's Bipolar Misdiagnosis? | MedPage Today
Sage Therapeutics, Shionogi ink deal for MDD treatment
Sage surges after depression drug gets rapid path to approval - PMLiVE
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
Sage rethinks SAGE-217 program after phase 3 failure | Fierce Biotech
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Business Wire
Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics surges 70% after depression drug breakthrough
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage advice: psychiatric drug development is tough | Evaluate
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Sage advice: psychiatric drug development is tough | Evaluate
PDF) Sage Therapeutics-Sitting On The Brink Of CNS Breakthroughs
Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
